Modern management of arrhythmias

Postgraduate Medical Journal

Volumn 82, Issue 964, 2006, Pages 117-125

  Hall, M C S ^b   Todd, D M ^a  

^a LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

^b Manchester Heart Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

BRUGADA SYNDROME; CATHETER ABLATION; DEFIBRILLATOR; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; LONG QT SYNDROME; MEDICAL SPECIALIST; REVIEW; SUDDEN DEATH; SYSTEMATIC REVIEW;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CATHETER ABLATION; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; HUMANS;

EID: 33144466094     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2005.033654     Document Type: Review

References (74)

1. Morady F. Catheter ablation of supraventricular arrhythmias: state of the art. Pacing Clin Electrophysiol 2004;27:125-42.
2. Shah DC, Haissaguerre M, Takahashi A, et al. Differential pacing for distinguishing block from persistent conduction through an ablation line. Circulation 2000;102:1517-22.
3. Shah DC, Takahashi A, Hocini M, et al. Local electrogram-based criteria of cavotricuspid isthmus block. J Cardiovasc Electrophysiol 1999;10:662-9.
4. Cauchemez B, Haissaguerre M, Fischer B, et al. Electrophysiological effects of catheter ablation of inferior cava-tricuspid annulus isthmus in common atrial flutter. Circulation 1996;93:284-94.
5. Natale A, Newby KH, Pisano E, et al. Prospective randomized comparison of antiarrhythmic therapy versus radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol 2000;35:1898-904.
6. Nabar A, Rodriguez LM, Timmermans C, et al. Effect of right atrial isthmus ablation on the occurrence of atrial fibrillation: observations in four patients having type I atrial flutter with or without associated atrial fibrillation. Circulation 1999;99:1441-5.
7. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study. Arch Intern Med 1987;145:1561-4.
8. Wolf P, Mitchell J, Baker C, et al. Impact of atrial fibrillation on mortality, stroke and medical costs. Arch Intern Med 1998;158:229-34.
9. Reimold SC, Cantillon CO, Friedman PL, et al. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993;71:558-63.
10. Coplen SE, Antman EM, Berline JA, et al. Efficacy and safely of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82:1106-16.
11. Flaker GC, Blackshear JL, Kronmal RA, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992;20:527-32.
12. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm control in persistent atrial fibrillation: the strategies of treatment of atrial fibrillation (STAF) study. J Am Coll Cardiol 2003;41:1690-6.
13. Van Gelder IC, Hogens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
14. Wyse DG, Waldo A, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
15. Hohnloser SH, Kuck KH. Randomized trial of rhythm or rate control in atrial fibrillation: the pharmacological intervention in atrial fibrillation trial (PIAF). Eur Heart J 2001;22:801-2.
16. Crystal E, Connolly SJ. Role of oral anticoagulation in management of atrial fibrillation. Heart 2004;90:813-17.
17. Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function. Circulation 2001;104:292-6.
18. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Circulation 1998;104:292-6.
19. Cox JL, Schuessler RB, Lappas DG, et al. An 8 1/2-year clinical experience with surgery for atrial fibrillation. Ann Surg 1996;224:267-73.
20. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66.
21. Shah DC, Haissoguerre M, Jais P. Current perspectives on curative catheter ablation of atrial fibrillation. Heart 2002;87:6-8.
22. Shah DC, Haissaguerre M, Jais P, et al. Electrophysiologically guided ablation of the pulmonary veins for the curative treatment of atrial fibrillation. Ann Med 2000;32:408-16.
23. Pappone C, Oreto G, Rosiano S, et al. Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation 2001;104:2539-44.
24. Pappone C, Rosiano S, Oreto G, et al. Circumferential radiofrequency ablation of pulmonary vein ostia: a new anatomic approach for curing atrial fibrillation. Circulation 2000;102:2619-28.
25. Oral H, Scharf C, Chugh A, et al. Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation. Circulation 2003;108:2355-60.
26. Hsu LF, Jais P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004;351:2373-83.
27. Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003;42:185-97.
28. Bourke JP, Dunuwille A, O'Donnell D, et al. Pulmonary vein ablation for idiopathic atrial fibrillation: six month outcome of first procedure in 100 consecutive patients. Heart 2005;91:51-7.
29. Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy and safety of catheter ablation for human atrial fibrillation. Circulation 2005;111:1100-5.
30. Demirovk J, Myerburg RJ. Epidemiology of sudden cardiac death: an overview. Prog Cardiovasc Dis 1994;37:39-48.
31. Latorre Fd, Nolan J, Robertson C, et al. European Resuscitation Council Guidelines 2000 for advanced adult life support. Resuscitation 2001;48:211-21.
32. The AVID investigators. A comparison of anti-arrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-84.
33. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardaic arrest. The cardiac arrest study Hamburg (CASH). Circulation 2000;102:748-54.
34. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-302.
35. Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta analysis. J Am Coll Cardiol 2003;41:1573-82.
36. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Eur Heart J 2000;21:2071-8.
37. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933-40.
38. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-90.
39. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
40. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;253:225-37.
41. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
42. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE guideline update for implantation of cardiac pacemakers and antiarrhythmia devices. J Cardiovasc Electrophysiol 2002;13:1183-99.
43. The CASCADE investigators. Randomised antiarrhythmic therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993;72:280.
44. Mason JW. A comparison of electropnysiologic testing with Holten monitoring to predict antiarrhythmic drug efficacy for ventricular arrhythmias. N Engl J Med 1993;329:445-51.
45. Echt DS, Liebson PR, Mitchell LB. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med 1991;324:781-8.
46. Haverkamp W, Matinez-Rubio A, Hief C, et al. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. J Am Coll Cardiol 1997;30:487-95.
47. Sim I, McDonald KM, Lavori PW, et al. Qualitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 1997;96:2823-9.
48. Boriani G, Lubinski A, Capucci A, et al. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur Heart J 2001;22:2180-91.
49. Brugada P, Brugada J. Right bundle branch block, persistent ST elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992;20:1391-6.
50. Alings M, Wilde A. A "Brugada" syndrome: Clinical data and suggested pathophysiological mechanism. Circulation 1999;99:666-73.
51. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST elevation and right bundle branch block but structurally normal hearts. Circulation 2000;101:510-15.
52. Brugada J, Brugada R, Antzelevitch C, et al. Long-term follow up of individuals with the electrocardiographic pattern of right bundle branch block and ST-segment elevation in precordial leads V1-V3. Circulation 2002;105:73-8.
53. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002;105:1342-7.
54. Matsuo K, Kurita M, Inagaki M, et al. The arcadian pattern to the development of ventricular fibrillation in patients with Brugada syndrome. Eur Heart J 1999;20:465-70.
55. Brugada J, Brugada R, Brugada P. Right bundle branch block and ST-segment elevation in leads VI through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998;97:457-60.
56. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2001;22:1374-450.
57. Moss AJ. Long QT syndrome. JAMA 2003;289:2041-4.
58. Zareba W, Moss AJ, le Cessie A, et al. Risk of cardiac events in family members of patients with long QT syndrome. J Am Coll Cardiol 1995;26:1685-91.
59. Priori SG, Rivolta I, Napolitano C. Genetics of long QT, Brugada and other channelopathies. In: Zipes DP, Jalife J, eds. Cardiac electrophysiology: from cell to bedside. 4th ed. Philadelphia: Sounders, 2004:462-70.
60. Chiang CE, Roden DM. The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol 2000;36:1-12.
61. Locati EH, Zareba W, Moss AJ, et al. Age and sex-related differences in clinical manifestations in patients with congenital long QT syndrome. Circulation 1998;97:2237-44.
62. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348:1866-74.
63. Moss AJ, Robinson JL, Gessmann L, et al. Comparison of clinical and genetic variables of cardiac events associates with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol 1999;84:876-9.
64. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta blocker therapy in congenital long QT syndrome. Circulation 2000;101:616-23.
65. Dorostkar PC, Eldar M, Belhassen B, et al. Long term follow up of patients with long QT syndrome treated with beta blockers and continuous pacing. Circulation 1999;100:2431-6.
66. Wilber DJ, Baerman J, Olshansky B, et al. Adenosine sensitive ventricular tachycardia: clinical characteristics and response to catheter ablation. Circulation 1993;87:126-34.
67. O'Donnell D, Cox D, Bourke JP, et al. Clinical and electrophysiological differences between patients with arrhythmogenic right ventricular dysplasia and right ventricular outflow tract tachycardia. Eur Heart J 2003;24:801-10.
68. Nakagawa H, Beckmann KJ, McClelland JH, et al. Radiofrequency ablation of idiopathic left ventricular tachycardia guided by a Purkinje potential. Circulation 1993;88:2607.
69. Stevenson WG, Nademanee K, Weiss JN, et al. Treatment of catecholamine-sensitive right ventricular tachycardia by catheter ablation. J Am Coll Cardiol 1990;16:752.
70. Wellens HJ, Smeets JL. Idiopathic left ventricular tachycardia: cure by radiofrequency ablation. Circulation 1993;88:2978.
71. Schilling RJ, Peters NS, Davies DW. Feasibility of a noncontact catheter for endocardial mapping of ventricular tachycardia. Circulation 1999;99:2543-52.
72. O'Donnell D, Bourke JP, Anilkumar R, et al. Radiofrequency ablation for post infarction ventricular tachycardia. Eur Heart J 2002;23:1699-705.
73. Arenal A, Glez-Torrecilla E, Ortiz M, et al. Ablation of electrograms with an isolated, delayed component as treatment of unmappable monomorphic ventricular tachycardias in patients with structural heart disease. J Am Coll Cardiol 2003;41:81-92.
74. Stevenson WG, Friedman PL, Kocovic D, et al. Radiofrequency catheter ablation of ventricular tachycardia after myocardial infarction. Circulation 1998;98:308.